Orexigen Therapeutics Inc

Orexigen Therapeutics — Cantor Fitzgerald Healthcare Conference 2017

36 slides from Orexigen Therapeutics's conference presentation, Sep 26, 2017

  1. Slide 1: Cantor Fitzgerald Healthcare Conference

    Slide 1: Cantor Fitzgerald Healthcare Conference

    Cantor Fitzgerald Healthcare Conference Michael Narachi Chief Executive Officer September 27, 2017 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its Contrave® product. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and sim

  3. Slide 3: Indication and boxed warning for Contrave

    Slide 3: Indication and boxed warning for Contrave

    Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio

  4. Slide 4: Overall Business Performance: Key Takeaways

    Slide 4: Overall Business Performance: Key Takeaways

    First year results after re-purchasing US rights from our former partner are very positive, with about half of the prior spend Aided by Orexigen’s consumer-focused campaign, Contrave achieved new all time highs in volume, share, and net revenue per Rx Reported strong Q1 and Q2 net sales and TRx grow

  5. Slide 5: Contrave Weekly Market Share

    Slide 5: Contrave Weekly Market Share

    Contrave Weekly Market Share Source: QuintilesIMS NPA Weekly, Week Ending 09/15/17 Contrave Belviq Qsymia Saxenda Note: Digital and Print Ads are still active after 2nd week of May

  6. Slide 6: Branded Market TRx Volume

    Slide 6: Branded Market TRx Volume

    Branded Market TRx Volume Source: QuintilesIMS NPA Weekly, Week Ending 09/15/17 Contrave Belviq Qsymia Saxenda Note: Digital and Print Ads are still active after 2nd week of May

  7. Slide 7: Strong US Sales Growth Driven by Increasing TRx Volume and Revenue/Unit

    Slide 7: Strong US Sales Growth Driven by Increasing TRx Volume and Revenue/Unit

    Strong US Sales Growth Driven by Increasing TRx Volume and Revenue/Unit Net Sales $M Note: Orexigen assumed commercial responsibility August 1, 2016 Quarterly Net Sales TRx (000) Quarterly TRxs +40% +18% +23% +40% +21% vs. PY +69% vs. PY Source: Orexigen reported sales, IMS NPA All-time high All-tim

  8. Slide 8: We Project Strong Double Digit Growth of Contrave

    Slide 8: We Project Strong Double Digit Growth of Contrave

    We Project Strong Double Digit Growth of Contrave Source: IMS NPA; Orexigen estimates. TRx Volume

  9. Slide 9: September 2017: Applying Our First Year Learnings to Our Second Year

    Slide 9: September 2017: Applying Our First Year Learnings to Our Second Year

    September 2017: Applying Our First Year Learnings to Our Second Year

  10. Slide 10: September 2017 Commercial Campaign

    Slide 10: September 2017 Commercial Campaign

    Plan to activate patients during the Fall season where “back to school, back to routine, back to you” themes can activate weight loss patients Focus patients on Telemedicine and Free Home Delivery via “Get Contrave Now” Main activity runs from mid August to mid October Key Elements of Plan: Fall Sea

  11. Slide 11: End-to-end Telemedicine Process for Contrave

    Slide 11: End-to-end Telemedicine Process for Contrave

    Orexigen is driving a fundamental change in the patient journey Branded Site: Contrave Digital Activation Broadcast TV * The online doctor consult and free home delivery services are offered by our partners Patient chooses preferred HCP interaction Patient Visits HCP Office Traditional eRx Patient P

  12. Slide 12: New Call to Action for Get Contrave Now

    Slide 12: New Call to Action for Get Contrave Now

    New Call to Action for “Get Contrave Now” with getcontravenow.com URL that directs to contrave.com homepage – in all TV/Digital DTC ads Broadcast TV “Now you can talk to a doctor online and get free shipping at getcontravenow.com” (URL directs to homepage)

  13. Slide 13: Revised TV Advertising

    Slide 13: Revised TV Advertising

    Revised TV: “Now you can talk to a doctor online and get free shipping at getcontravenow.com” “Lose weight and keep it off with Contrave” “Contrave is believed to work on two areas of the brain: Your hunger center “I’m so hungry” to reduce hunger. And your reward system…”ice cream, French fries” to

  14. Slide 14: Revised Digital Display 60-Second Video

    Slide 14: Revised Digital Display 60-Second Video

    Revised Digital Display 60-Second Video Revised 60-Second Video with “Get Contrave Now” is running across all partners currently Any place on both the video and banner is clickable throughout the entire video Targeting tactics include: Retargeting site visitors in last 30 days regardless of action t

  15. Slide 15: Contrave Targeting

    Slide 15: Contrave Targeting

    CONTRAVE Targeting Conquesting Intercept consumers who researched, purchased, or showed intent of a non-Rx or Rx competitor Site Retargeting Consumer Visits CONTRAVE.com, may or may not take a key action or high value conversion Retargeting partner finds consumer during online activity Lookalike/Pro

  16. Slide 16: New Social Get Contrave Now Ads

    Slide 16: New Social Get Contrave Now Ads

    New Social “Get Contrave Now” Ads 16 The entire campaign incorporates key safety and risk information including the boxed warning for suicidal thoughts and behaviors

  17. Slide 17: Cravings Swap Social Posts

    Slide 17: Cravings Swap Social Posts

    “Cravings Swap” – Retargeting audiences who are aware of Contrave on Facebook and Instagram New Social Posts Focused on Cravings 17 The entire campaign incorporates key safety and risk information including the boxed warning for suicidal thoughts and behaviors

  18. Slide 18: Sales Force: In-Office Promotion Focus

    Slide 18: Sales Force: In-Office Promotion Focus

    Narrowed promotional effort to top Contrave writers Importance of Early Control of Cravings Expand patient type to include on-label lower BMI patients (sell to full indication) Proactive promotion of free home delivery Market Access Pull Through: As of 09/01, Contrave is the exclusive product prefer

  19. Slide 19: Key Sales Force Messages

    Slide 19: Key Sales Force Messages

    Key Sales Force Messages Patients struggle with hunger AND cravings Cravings can derail patients Contrave works on two areas of the brain… Naltrexone and bupropion, >30yrs in addiction… Differentiated MOA Patients adding Contrave lost 2-4X more weight than diet and exercise alone, 25lbs, 4.4in Safet

  20. Slide 20: Fall Campaign: Early Results

    Slide 20: Fall Campaign: Early Results

    Fall Campaign: Early Results

  21. Slide 21: Fall Campaign - Key Performance Metrics

    Slide 21: Fall Campaign - Key Performance Metrics

    Fall Campaign - Key Performance Metrics Overall Performance TRx: Volume and Share NBRx: Volume and Share Therapy Starts Brand Switch Digital Performance Website Traffic: Volume and Source Key Actions: Volume and KA Rate FAD Page Views GCN Page Views Doctor Discussion Guide Page Views Savings Card Pa

  22. Slide 22: Contrave.com traffic volume increased >80%

    Slide 22: Contrave.com traffic volume increased >80%

    Contrave.com traffic volume increased >80% vs. the average of last the four weeks prior to September SOURCE: Google Analytics , Approved CONTRAVE Media 2017 Media Plan Total sessions are one day off (e.g. sessions Sunday-Saturday due to GA processing limitations. Off Season, No TV Avg. = 63K During

  23. Slide 23: Get Contrave Now page views increased nearly 4X

    Slide 23: Get Contrave Now page views increased nearly 4X

    SOURCE: Google Analytics , Approved CONTRAVE Media 2017 Media Plan Updating the Call to Action has increased “Get Contrave Now” Page Views nearly 4X vs. the average volume in August Fall TV Campaign Starts

  24. Slide 24: Telemedicine and Home Delivery New Prescription and Refill Rates

    Slide 24: Telemedicine and Home Delivery New Prescription and Refill Rates

    Source: Orexigen Therapeutics Telemedicine and Home Delivery New Prescription and Refill Rates Supported by Customer Service Model Week Ending Contrave GCN Fulfillments – New Rx and Refills Fall TV Campaign Starts

  25. Slide 25: OUS Commercial Update

    Slide 25: OUS Commercial Update

    ts OREXIGEN OUS Commercial Update

  26. Slide 26: Now Partnered in Countries Outside the U.S.

    Slide 26: Now Partnered in Countries Outside the U.S.

    Now Partnered in 48 Countries Outside the U.S. South Korea Central & Eastern Europe Spain Canada Aus/ NZ South Africa 3Q 15 4Q 15 1Q 16 2Q 16 3Q 16 4Q 16 UK Ireland Middle East 2017 Goal: Add 10-15 additional countries, with a focus on Latin America and Europe 2Q 17 Italy 1Q 17 Nordics 3Q 17 Egypt A

  27. Slide 27: Launched in 17 Countries Outside the U.S.

    Slide 27: Launched in 17 Countries Outside the U.S.

    Submissions Launches 4Q 17 3Q 17 2Q 17 1Q 17 4Q 16 3Q 16 2Q 16 1Q 16 Saudi Arabia Lebanon UAE Kuwait Serbia South Africa Saudi Arabia Australia Canada Lebanon UAE Kuwait Greece United Kingdom Ireland Spain Bulgaria Estonia Lithuania Latvia Croatia Slovenia Korea Czech Republic Slovakia Hungary Polan

  28. Slide 28: Financial Update

    Slide 28: Financial Update

    ts OREXIGEN Financial Update

  29. Slide 29: Second Quarter 2017 Financial Results

    Slide 29: Second Quarter 2017 Financial Results

    Second Quarter 2017 Financial Results Revenue of $23.4M $20.7M in US net sales of Contrave, a 69% increase compared to Q2 2016a $2.7M in OUS net sales of Contrave to partners US average net revenue per unit sold of approximately $96, a 37% increase compared to Q2 2016 Cost of Product Sales of $6.8M,

  30. Slide 30: 2017 Net Sales Expectations

    Slide 30: 2017 Net Sales Expectations

    2017 Net Sales Expectations 2017 Guidance Orexigen Net Sales $85M - $100M US Net Sales $75M - $85M OUS Net Sales $10M - $15M Partner-Reported OUS Net Sales of Contrave / Mysimba $10M - $15M

  31. Slide 31: 2017 Expense Guidance

    Slide 31: 2017 Expense Guidance

    2017 Expense Guidance Notes: Defined as GAAP operating expense less stock compensation, depreciation, and other non-cash expenses outside the normal course of business operations Includes the following areas: Research, Development, Regulatory Affairs, Safety, Technical Operations and Quality Cash, c

  32. Slide 32: Overall Business Performance: Key Takeaways

    Slide 32: Overall Business Performance: Key Takeaways

    First year results after re-purchasing US rights from our former partner are very positive, with about half of the prior spend Aided by Orexigen’s consumer-focused campaign, Contrave achieved new all time highs in volume, share, and net revenue per Rx Reported strong Q1 and Q2 net sales and TRx grow

  33. Slide 33: Appendix

    Slide 33: Appendix

    Appendix

  34. Slide 34: Non-GAAP financial measures explanation

    Slide 34: Non-GAAP financial measures explanation

    This presentation includes information relating to non-GAAP operating expense and non-GAAP operating results, which the Securities and Exchange Commission has defined as "non-GAAP financial measures." Non-GAAP operating expense and non-GAAP operating results have been included in this presentation b

  35. Slide 35: Reconciliation of GAAP to Non-GAAP Financial Measures

    Slide 35: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures R&D Sales & Marketing G&A Amortization Expense of Intangible Assets Change in Fair Value of Contingent Consideration Total GAAP Operating Expense $7,509 $38,128 $10,183 $1,984 $700 $58,504 Stock Compensation ($301) ($810) ($1,443) --- --- ($2,554

  36. Slide 36: Reconciliation of GAAP to Non-GAAP Operating Loss

    Slide 36: Reconciliation of GAAP to Non-GAAP Operating Loss

    Reconciliation of GAAP to Non-GAAP Operating Loss Reconciliation of GAAP to non-GAAP Operating Loss Three Months Ended June 30, 2017 ($000) Three Months Ended June 30, 2016 ($000) GAAP Operating Loss ($41,990) ($33,233) Amortization Expense of Intangible Assets $1,984 --- Change in Fair Value of Con

Source: SEC EDGAR · 8-K filed Sep 26, 2017

More decks from Orexigen Therapeutics Inc